PCIB Stock Overview
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.
PCI Biotech Holding Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr4.11|
|52 Week High||kr28.92|
|52 Week Low||kr4.00|
|1 Month Change||-6.06%|
|3 Month Change||-18.71%|
|1 Year Change||-82.91%|
|3 Year Change||-85.75%|
|5 Year Change||-82.07%|
|Change since IPO||-77.19%|
Recent News & Updates
We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|PCIB||NO Biotechs||NO Market|
Return vs Industry: PCIB underperformed the Norwegian Biotechs industry which returned -48.9% over the past year.
Return vs Market: PCIB underperformed the Norwegian Market which returned 12.6% over the past year.
|PCIB Average Weekly Movement||7.8%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||7.4%|
|10% most volatile stocks in NO Market||12.4%|
|10% least volatile stocks in NO Market||4.2%|
Stable Share Price: PCIB is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PCIB's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin.
PCI Biotech Holding Fundamentals Summary
|PCIB fundamental statistics|
Is PCIB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PCIB income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 31, 2022
|Earnings per share (EPS)||-2.35|
|Net Profit Margin||-12,221.76%|
How did PCIB perform over the long term?See historical performance and comparison
Is PCI Biotech Holding undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PCIB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PCIB's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: PCIB is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: PCIB is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PCIB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PCIB is good value based on its PB Ratio (1.7x) compared to the NO Biotechs industry average (3.9x).
How is PCI Biotech Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PCI Biotech Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has PCI Biotech Holding performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PCIB is currently unprofitable.
Growing Profit Margin: PCIB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PCIB is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare PCIB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PCIB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-5.2%).
Return on Equity
High ROE: PCIB has a negative Return on Equity (-98.68%), as it is currently unprofitable.
How is PCI Biotech Holding's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PCIB's short term assets (NOK107.7M) exceed its short term liabilities (NOK19.5M).
Long Term Liabilities: PCIB's short term assets (NOK107.7M) exceed its long term liabilities (NOK1.1M).
Debt to Equity History and Analysis
Debt Level: PCIB is debt free.
Reducing Debt: PCIB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PCIB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PCIB has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 18.2% each year.
What is PCI Biotech Holding current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PCIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PCIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PCIB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PCIB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PCIB has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Per Walday (61 yo)
Dr. Per Walday, Ph D., has been the Chief Executive Officer at PCI Biotech AS since 2008. He serves as Chief Executive Officer at EXACT Therapeutics AS since March 28, 2022.Dr. Walday has been the Chief E...
CEO Compensation Analysis
Compensation vs Market: Per's total compensation ($USD296.79K) is about average for companies of similar size in the Norwegian market ($USD330.08K).
Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.
Experienced Management: PCIB's management team is seasoned and experienced (5.9 years average tenure).
Experienced Board: PCIB's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PCI Biotech Holding ASA's employee growth, exchange listings and data sources
- Name: PCI Biotech Holding ASA
- Ticker: PCIB
- Exchange: OB
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr153.225m
- Shares outstanding: 37.33m
- Website: https://www.pcibiotech.com
Number of Employees
- PCI Biotech Holding ASA
- UllernchaussEen 64
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.